Zafrens

Developing an ultra-high-throughput experimental platform that generates rich biological data to test and validate drug discovery hypotheses at scale.

At a glance

Year of investment: 2026
Stage: Growth Stage
Investment Strategy: Ventures
Impact Theme: Healty People
Sector: TechBio

Website

Business description

Advances in computational biology and AI are rapidly increasing the ability to generate hypotheses and predict potential drug candidates, while creating a growing need for experimental approaches capable of validating these predictions in complex biological systems.

Zafrens’ proprietary Z-Screen platform addresses this need by combining microfluidics, longitudinal cell imaging and sequencing to connect molecular information with cellular function at ultra-high throughput. This enables biological hypotheses to be tested and validated with a scale and depth of experimental data that have historically been difficult to achieve.

"Zafrens has reached an important inflection point as we translate the extraordinary scale and resolution of our platform into drug discovery programs with the potential to generate meaningful new medicines. We are delighted to welcome Trill Impact to Zafrens as we enter this next phase of the company’s development.”

- Swamy Vijayan, Founder and CEO of Zafrens

Zafrens' solution

Social/Environmental challenge

Drug discovery remains a lengthy, costly and highly uncertain process, with many potential medicines failing during development. By enabling earlier and more efficient validation of drug candidates, Zafrens has the potential to reduce the time and resources required in drug discovery and support better-informed decisions about which candidates progress into development. Ultimately, this could contribute to the development of more effective medicines and better outcomes for patients

SDG Contribution

Zafrens’ activities contribute primarily to:

SDG #3 Good Health and Well-being, including target 3.4 on reducing premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-being.

SDG #9 Industry, innovation and infrastructure, including target 9.5 on enhancing scientific research and technological capabilities

Trill Impact News

Press release

03 november 2026

Trill Impact Ventures leads Zafrens’ USD 6 million Series A extension round to advance next-generation drug discovery

Accelerating the path from biological insight to new medicines

See all articles here